Cambridge Investment Research Advisors’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.3M Buy
156,694
+11,293
+8% +$911K 0.03% 554
2026
Q1
$10.3M Buy
145,401
+25,229
+21% +$1.89M 0.03% 606
2025
Q4
$9.49M Sell
120,172
-713
-0.6% -$56.4K 0.03% 607
2025
Q3
$9.96M Buy
120,885
+6,044
+5% +$476K 0.03% 570
2025
Q2
$9.23M Buy
114,841
+2,704
+2% +$209K 0.03% 571
2025
Q1
$9M Buy
112,137
+5,413
+5% +$450K 0.03% 550
2024
Q4
$8.74M Buy
106,724
+4,346
+4% +$362K 0.03% 540
2024
Q3
$8.44M Buy
102,378
+9,782
+11% +$731K 0.03% 565
2024
Q2
$6.5M Buy
92,596
+10,057
+12% +$718K 0.02% 637
2024
Q1
$6.12M Buy
82,539
+4,040
+5% +$282K 0.02% 647
2023
Q4
$5.19M Buy
78,499
+5,707
+8% +$357K 0.02% 682
2023
Q3
$4.58M Buy
72,792
+21,613
+42% +$1.35M 0.02% 697
2023
Q2
$2.89M Sell
51,179
-7,014
-12% -$389K 0.01% 951
2023
Q1
$3.37M Buy
58,193
+9,516
+20% +$642K 0.02% 825
2022
Q4
$3.52M Buy
48,677
+1,690
+4% +$121K 0.02% 770
2022
Q3
$2.86M Buy
46,987
+3,067
+7% +$196K 0.02% 844
2022
Q2
$2.76M Buy
43,920
+1,315
+3% +$87K 0.01% 881
2022
Q1
$2.99M Buy
42,605
+2,181
+5% +$147K 0.01% 915
2021
Q4
$2.53M Buy
40,424
+584
+1% +$36.7K 0.01% 1018
2021
Q3
$2.46M Buy
39,840
+2,016
+5% +$121K 0.01% 984
2021
Q2
$2.26M Sell
37,824
-8,050
-18% -$510K 0.01% 1040
2021
Q1
$2.79M Buy
45,874
+3,089
+7% +$170K 0.02% 837
2020
Q4
$2.01M Sell
42,785
-3,977
-9% -$172K 0.01% 919
2020
Q3
$1.74M Sell
46,762
-703
-1% -$26.7K 0.01% 879
2020
Q2
$1.73M Buy
47,465
+1,475
+3% +$51.3K 0.01% 835
2020
Q1
$1.41M Sell
45,990
-4,954
-10% -$220K 0.01% 809
2019
Q4
$2.6M Buy
50,944
+1,082
+2% +$52.2K 0.02% 677
2019
Q3
$2.35M Buy
49,862
+7,391
+17% +$352K 0.02% 681
2019
Q2
$2.11M Buy
42,471
+2,377
+6% +$112K 0.02% 688
2019
Q1
$1.71M Sell
40,094
-2,675
-6% -$118K 0.02% 781
2018
Q4
$1.76M Sell
42,769
-22,047
-34% -$946K 0.02% 684
2018
Q3
$3.03M Sell
64,816
-1,840
-3% -$84.1K 0.03% 522
2018
Q2
$2.91M Sell
66,656
-14,714
-18% -$686K 0.03% 516
2018
Q1
$3.73M Buy
81,370
+9,239
+13% +$448K 0.04% 400
2017
Q4
$3.65M Buy
72,131
+10,513
+17% +$554K 0.04% 389
2017
Q3
$3.2M Sell
61,618
-1,150
-2% -$56K 0.04% 390
2017
Q2
$3.07M Buy
62,768
+1,248
+2% +$57.9K 0.05% 378
2017
Q1
$2.9M Buy
61,520
+5,359
+10% +$255K 0.05% 346
2016
Q4
$2.7M Sell
56,161
-3,074
-5% -$141K 0.05% 348
2016
Q3
$2.35M Buy
59,235
+22,678
+62% +$853K 0.04% 384
2016
Q2
$1.3M Sell
36,557
-6,814
-16% -$266K 0.03% 495
2016
Q1
$1.7M Sell
43,371
-223
-0.5% -$8.34K 0.04% 398
2015
Q4
$1.87M Buy
43,594
+5,557
+15% +$244K 0.04% 372
2015
Q3
$1.6M Buy
38,037
+4,396
+13% +$205K 0.05% 356
2015
Q2
$1.68M Buy
33,641
+4,438
+15% +$210K 0.05% 352
2015
Q1
$1.32M Buy
29,203
+2,213
+8% +$99.4K 0.04% 416
2014
Q4
$1.3M Buy
26,990
+796
+3% +$37.8K 0.04% 408
2014
Q3
$1.25M Buy
26,194
+2,892
+12% +$140K 0.04% 439
2014
Q2
$1.15M Buy
23,302
+715
+3% +$33.5K 0.04% 415
2014
Q1
$1.06M Buy
22,587
+7,588
+51% +$349K 0.04% 406
2013
Q4
$721K Buy
14,999
+1,962
+15% +$88K 0.03% 503
2013
Q3
$546K Buy
13,037
+1,319
+11% +$56.8K 0.02% 589
2013
Q2
$478K Buy
+11,718
New +$431K 0.02% 566

Other funds holding MET

Cambridge Investment Research Advisors's MET Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its MetLife (MET) stake by 7.8% in Q2 2026, buying an estimated $911K and bringing the position to 156,694 shares worth $13.3M. The position accounts for 0.03% of the portfolio, ranked #554.

Cambridge Investment Research Advisors first reported a position in MET in Q2 2013 and has held it in 53 quarters since. 1,450 funds tracked by Wall St. Rank hold MET as of Q2 2026.

  • Cambridge Investment Research Advisors held 156,694 shares of MetLife worth $13.3M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 11,293 MetLife shares in Q2 2026, an estimated $911K.
  • MetLife made up 0.03% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #554 holding.
  • Cambridge Investment Research Advisors first reported a position in MetLife in Q2 2013 and has held it in 53 quarters since.
  • 1,450 funds tracked by Wall St. Rank held MetLife as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.